Review Article
The Effects of Mesenchymal Stem Cell on Colorectal Cancer

Jintao Yuan,1 Zhiping Wei,2 Xinwei Xu,2 Dickson Kofi Wiredu Ocansey,2,3 Xiu Cai,2 and Fei Mao2

1The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Zhenjiang, Jiangsu 212300, China
2Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, 212013 Jiangsu, China
3Directorate of University Health Services, University of Cape Coast, Cape Coast, Ghana

Correspondence should be addressed to Fei Mao; maofei2003@ujs.edu.cn

Received 18 May 2021; Accepted 13 July 2021; Published 26 July 2021

Academic Editor: Jian Fang

Colorectal cancer (CRC) is a common malignant tumor of the gastrointestinal tract with nonobvious early symptoms and late symptoms of anemia, weight loss, and other systemic symptoms. Its morbidity and fatality rate are next only to gastric cancer, esophageal cancer, and primary liver cancer among digestive malignancies. In addition to the conventional surgical intervention, other therapies such as radiotherapy and chemotherapy and new treatment methods such as biologics and microbiological products have been introduced. As a promising cell therapy, mesenchymal stem cell (MSC) has attracted extensive research attention. MSCs are early undifferentiated pluripotent stem cells, which have the common features of stem cells, including self-replication, self-division, self-renewal, and multidirectional differentiation. MSCs come from a wide range of sources and can be extracted from a variety of tissues such as the bone marrow, umbilical cord, and fat. Current studies have shown that MSCs have a variety of biological functions such as immune regulation, tissue damage repair, and therapeutic effects on tumors such as CRC. This review outlines the overview of MSCs and CRC and summarizes the role of MSC application in CRC.

1. Introduction

Since the discovery of MSCs, researchers have deeply discussed their physiological characteristics. According to the definition of the International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell (ISCT MSC) committee, MSCs are different from mesenchymal stromal cells [1]. MSCs are heterogeneous cell groups with the ability of self-renewal and differentiation. Besides bone marrow-derived MSCs (BM-MSCs) and umbilical cord-derived MSCs (UC-MSCs), which are widely studied, there are several other sources of MSCs including peripheral blood, adipose tissue, and minced pulp tissues [2–5]. According to their donors and passages, MSCs derived from diverse sources have different surface markers. The ISCT committee suggests that the minimum criteria for identification is plastic adhesion, the ability to express CD73, CD90, and CD105, but not expressing CD11b, CD14, CD19, CD34, CD45, CD79a, and HLA-DR [1, 6].

Compelling evidence indicates that MSCs have great potential in regenerative medicine. MSCs can participate in tissue repair and regeneration [7], immune homeostasis regulation [8], inflammation resistance, and tumor inhibition [9, 10]. Exosomes derived from MSCs, as one of the paracrine products, have attracted researchers’ attention recently because of their similar functions to MSCs. Exosomes, the 30-150 nm vesicles, are formed by endocytosis of cells, which encapsulate nucleic acids, proteins, lipids, and metabolites from the original cells when discharged from them [11, 12]. It has been found that exosomes can participate in information transmission between cells through packaged biologically active substances such as nucleic acid and protein [13, 14]. Through receptors and ligands, exosomes target specific cells and achieve information exchange by their integration into cell membranes [15]. Exosomes derived from MSCs possess the functional ability to be applied for tissue damage repair and cancer inhibition and avoid the adverse reactions...
associated with cellular therapy [16–18]. As a cell-free therapy, exosomes have great prospects in cancer treatment.

CRC is among the top five cancers in the world in morbidity and mortality. Although the specific pathogenic factors that cause CRC remain unclear, its incidence is related to heredity, smoking, and eating pickled products, among other environmental factors [19, 20]. CRC begins insidiously and is usually screened for with stool tests, radiology, blood tests, and colonoscopy [21, 22]. Traditional chemotherapy has a poor curative effect on CRC with associated high toxicity and drug resistance [23]. Researchers have found that natural compounds, such as resveratrol and curcumin can treat CRC without huge adverse reactions through a series of animal models [24]. However, the lack of clinical trials hinders the application of these compounds. MSCs and their derived exosomes possess the ability to regulate the tumor microenvironment through paracrine and direct contact to inhibit CRC cells [25, 26]. MSCs can also be used as adjuvant therapy for tumor treatment, where they enhance the tumor cell-cytotoxic effect of antitumor drugs via cytokine secretion [27]. In this review, we aim to discuss the current knowledge of the effect of MSCs and their exosomes on CRC, including the mechanism of MSCs’ inhibitory function in the CRC microenvironment, and the tumor-promoting effect of MSCs that cannot be ignored. This will bring up-to-date data on the status of the effects of MSCs and MSC-derived exosomes on CRC.

2. Overview of MSCs

2.1. Sources of MSCs. MSC is favored by the field of regenerative medicine because of its ability of self-renewal and directional differentiation under specific regulations. The characteristics of MSCs differ according to their different sources. Studying the characteristics of MSCs may help better selection of the suitable source, regulate their differentiation, and perhaps reduce the side effects of clinical application.

The sources of MSCs are varied, among which BM-MSCs, UC-MSCs, and MSCs from adipose tissue (AD-MSCs) are the most widely explored and applied [2]. The bone marrow provides an abundant source of MSCs, although this sampling method is invasive and causes great pain to patients. Alternatively, femoral shaft MSCs obtained during total hip arthroplasty have similar characteristics to iliac crest aspirate MSCs and can secrete cytokines such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF) [28]. The method of extracting AD-MSCs is also invasive, while the success rate and colony frequency of isolating AD-MSCs are relatively high [2]. MSCs can also be separated from neonatal-related tissues, such as the umbilical cord, umbilical cord blood, placenta, and amniotic membrane [29]. MSCs derived from umbilical cord blood (UCB-MSCs) and UC-MSCs are separated from the umbilical cord-related tissue and are widely used because their collection causes no pain to patients. At the same time, UCB-MSCs have a relatively longer survival time and higher differentiation potential [2, 29]. MSCs from neonatal tissues have better application potential than those from adult tissues [30].

Other noninvasive sources of MSCs are MSCs derived from endothelium (eMSCs), Wharton’s Jelly (WJ-MSCs), and menstrual blood (MenSCs), which are considered to regulate the innate and adaptive immune system both in vivo and in vitro [31, 32]. MSCs derived from pluripotent stem cells (PSCs) have been shown to overlap with BM-MSCs in gene expression and have similar immunomodulatory and inflammatory suppressive functions. Most importantly, they have the highest proliferation efficiency and longer passage time, which can be widely used as the source of MSCs [33]. MSCs derived from dental tissue, including dental pulp (dPSCs) [34], periodontal ligament (PDLSCs), gingiva (GSCs), apical papilla (APSCs) [35], and dental follicles (DFSCs) [36], have not been widely studied, while they have great potential in dental tissue regeneration. Sufficient research on the source of MSCs can help in the selection of suitable MSCs for specific disease treatment, establish a matching culture and separation system, and accelerate the development of MSC therapy. The sources and characteristics of MSCs are summarized in Table 1.

2.2. Differentiation of MSCs. One of the reasons MSCs are popular in the field of regenerative medicine is their multiple differentiation ability. MSCs have the ability to differentiate into osteoblasts, chondroblasts, and adipocytes and even develop a relatively mature induction system for different target cells [54, 55]. The regulation of MSCs differentiation is a complex system involving series of factors including cytokines, transcription factors, and nucleic acids. In theory, MSCs can be differentiated into cells through precise regulation [56]. For example, the osteogenic differentiation of MSCs could be active through calcium signaling [57]; miR-27a is involved in the differentiation of MSCs from osteogenesis to adipogenesis in postmenopausal osteoporosis [58]; transcription factors, including Runt-related transcription factor 2 (Runx2), SRY-related high-mobility group box gene 9 (Sox9), the adipogenic-specific peroxisome proliferation-activated receptor y (PPARγ), the member of the helix-loop-helix family transcription factors, MyoD, and the GATA zinc finger transcription factor family, GATA4 and GATA6, play a significant role in the differentiation of MSCs as corroborated by Almalki and Agrawal [59]; intercellular adhesion molecule-1 (ICAM-1) has been shown to inhibit MSC differentiation into adipocytes by activating the extracellular signal-regulated kinase (ERK) pathway and maintain MSCs undergoing adipogenesis through the p38 pathway [60].

MSCs are recruited in injury repair, and their ability of multidirectional differentiation is used in the reconstruction of injured tissues, with most of such reports described in MSCs from autologous sources [61]. Allogeneic MSCs disappear soon after injection in vivo, which may limit their curative effect [62]. MSCs play a therapeutic role by secreting active factors, and their differentiation ability in vivo is rarely reported, although in vivo studies of MSCs in the tumor microenvironment have been explored [63]. In the tumor microenvironment, the differentiation of MSCs could result in tumor promotion. For example, the infiltration of multipotential MSCs was found during the transformation of...
human prostate tumor, which suggests a possible role of the multipotential differentiation in cancer promotion [64]. Researchers found that limiting MSCs’ differentiation potential may become a new target for cancer treatment [65]. It is revealed that CXCR4/TGF-β1 can mediate the self-differentiation of human BM-MSCs into cancer-related fibroblasts (CAFs) in CRC, thus playing a role in promoting cancer [66]. Research focuses on the differentiation function of MSCs in CRC which is conducive to finding more cancer targets; hence, more related research is needed to explore the field in search good CRC treatment.

2.3. General Effect of MSCs. From inflammation, infection, abnormal metabolism, immune disorder, and tissue damage to the tumor, MSCs have obvious curative effects in the treatment of these diseases. It is generally believed that MSCs exert therapeutic effects through direct contact and paracrine action, where MSC-derived extracellular vehicles (EVs) are reported as the mechanism behind these effects [67, 68]. In the immunoregulatory process, monocytes can rapidly phagocytize MSCs injected in vitro, changing their phenotype, expressing interleukin-1β (IL-1β) and programmed death ligand-1 (PD-L1), and reducing the expression of tumor necrosis factor-α (TNF-α). These monocytes can migrate through the whole body via the circulatory system and play a follow-up immunoregulation effect [69]. Macrophage phenotype could also respond to the effect of MSCs by switching from proinflammatory “M1” to anti-inflammatory “M2” [70]. TGF-β and polyethylene glycol (PEG)-2 secreted by MSCs complete this process through the Akt/FoxO1 pathway [71, 72]. At the same time, the direct contact between proinflammatory macrophages and MSCs can enhance the secretion of tumor necrosis factor-stimulated gene-6 (TSG-6), and the production of anti-inflammatory T cells and macrophages [73]. MSCs play a role in relieving pain, inhibiting inflammation, sustaining proliferation, and regenerating matrix and cartilage in the process of bone regeneration with the regulation of V-Akt murine thymoma viral oncogene homolog (AKT), ERK, and the serine/threonine kinase AMP-activated protein kinase (AMPK) signaling [74].

For the treatment of tumors, the role of MSCs is complex. Compelling evidence indicated that MSCs can play a role in the process of tumor suppression, tumor growth, and drug resistance. The microRNA-100 secreted by MSCs is related to the downregulation of vascular endothelial growth factor (VEGF) in tumor angiogenesis [75], and miR-23b promotes the dormancy of metastatic breast cancer cells [76]. However, microRNA does not always play a positive role in inhibiting tumors. This is confirmed by several studies including that of Wei et al., who reported that microRNA-375 increases the invasion and metastasis of CRC via regulating the target gene RECK [77]. The fusion of MSCs with benign tissue cells may be beneficial to the repair of tissue damage, but after MSCs are recruited into tumor tissues, the fusion with tumor cells may be related to tumor metastasis [78]. This means that the direct contact and paracrine pathway of MSCs may not be able to alleviate the tumor. Further studies are needed to explore the mechanism of MSCs’ functional effects to enhance the antitumor application of MSCs and avoid the tumor-promoting effect.

2.4. General Clinical Application of MSCs. With the deepening of the understanding of the mechanism of MSCs’ functions, their clinical application is gradually standardized, and their safety has been greatly improved. Therefore, clinical trials of MSCs are constantly carried out. Intravenous
injection and intralesional injection account for the majority of MSCs administration. A three-year follow-up after intravenous infusion of UC-MSCs showed there were no abnormalities in blood routine, liver and kidney function, and immunoglobulin in the treatment of rheumatic immune diseases. Moreover, the health index and joint function index significantly improved [79]. For patients with multiple sclerosis, MSCs can improve the quality of life of patients without serious adverse reactions, and intrathecal administration is more effective than intravenous injection [80, 81]. More MSC-related clinical trials presented so far in the field of the cardiovascular system, digestive system diseases, nervous system, and endocrine system prove its effectiveness (Table 2).

The reduction of side effects in the clinical use of MSCs does not mean that it is completely safe. More attention should be paid to the safety research of MSCs application. Matthey et al., demonstrated that one dose of intravenous allogeneic BM-MSCs is safe in patients with moderate to severe acute respiratory distress syndrome (ARDS) [82]. The safety and efficacy of the intravenous infusion of UC-MSCs in patients with heart failure are also demonstrated by Bartolucci et al. [83]. Researchers using modified MSCs to treat gastrointestinal cancer found that MSCs were safe and well tolerated in patients with gastrointestinal cancer. However, due to the small number of patients and the heterogeneity of tumors, the treatment received by patients may affect the interaction between tumor microenvironment and MSCs; no improvement in tumor activity was observed [84]. Another group of researchers found no dose-limiting toxicity in MSC treatment of prostate cancer, while the effectiveness is still worth further exploring [85]. There are few clinical applications of MSCs in tumor treatment, which may be due to the lack of standard MSCs separation and infusion standards, the inability to inhibit the tumor-promoting effect of MSCs, the lack of cognition of MSCs homing mechanism, and the heterogeneity of the tumor. In the application of tumor therapy, there is a need to explore MSCs and tumors for a long time.

3. Overview of CRC

3.1. The Pathogenesis of CRC. CRC is a heterogeneous malignant tumor of the colon and rectum, the fourth most common cancer around the world contributing to 9.7% of the global cancer burden [108] and the third most frequent malignant tumor in China [109]. Bad living habits and environmental pollution contribute to the prevalence of CRC. It is reported that up to 90% of the morbidity risk of CRC is related to environmental factors such as diet [110]. CRC occurrence is linked with inappropriate dietary habits such as high consumption of heme-iron foods and alcohol and low consumption of fruits, vegetables, fiber, fish, dairy products, and vitamin C. Furthermore, unhealthy lifestyles such as obesity and lack of exercise increase CRC risk [111].

Besides diet and lifestyle, genetics and certain diseases can also contribute to CRC. In all CRCs, the genetic predisposition genes with high cancer risk are 2–8%. When the pathogenic mutations in high- and moderate-penetrance genes are added, the ratio will rise to 6–10% [112]. The risk of developing CRC increases in patients with inflammatory bowel disease (IBD), where the inflammation involved with IBD serves as a hazard for CRC onset [110, 113, 114]. Diabetes is positively relevant to the risk of CRC in men (HR = 1.17; 95% CI: 1.08–1.26; I² = 0%) and women (HR = 1.13; 95% CI: 0.82–1.56; I² = 46%) [115]. Microsatellite instability and microRNAs play important roles in the occurrence of CRC [114, 116]. Furthermore, intestinal microbiota highly impacts the state of CRC, where a proper balance in the diversity and composition positively correlates with a good CRC prognosis [117, 118]. The influencing factors of CRC occurrence are shown in Figure 1.

Individual habits such as eating red meat and consuming alcohol increase CRC risk, while eating dairy products, fish, and vitamin C-rich foods reduces the risk. Intestinal flora also plays a dual role in the development of CRC. Gene mutation and some noncoding RNAs can promote the occurrence of CRC.

3.2. Current Therapeutic Interventions in CRC. In addition to surgery, there are several current and emerging treatment options for CRC including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, among others [119]. These CRC treatment interventions are summarized in Table 3.

4. MSC Studies on Tumors

The biological functions of MSCs have been studied and applied in clinical trials, including the study of their effects on tumors. A search of the terms “mesenchymal stem cell and tumor” in the PubMed database revealed a total of 594 documents published in nearly 15 years, from January 1st, 2006, to December 31st, 2020 (Figure 2). Further statistical analysis of the MSC studies on different tumors in the last 15 years showed approximately 8% of literature reports on the role of MSCs on CRC (Figure 3).

The increasing attention given to MSC studies correlates with the rising application in cancer studies. Over the past few years, the number of published researches on the effect of MSCs on tumors has steadily been increasing. This figure represents studies on MSCs and different tumors in the past 15 years, where CRC represents 8% of total studies. Those with a proportion less than 4% are classified as others.

5. The Effect of MSCs on CRC

According to the literature, MSCs possess a double-edged sword property on CRC. In effect, MSCs can significantly inhibit the proliferation, migration, and infiltration of tumor cells to prevent the occurrence and progression of CRC, while in other conditions, MSCs serve as promoting agents for CRC progression (Table 4).

5.1. Inhibitory Effects on CRC. Studies show that under certain treatment conditions, MSCs can inhibit the proliferation of CRC cells and promote apoptosis, thus inhibiting the
progression of CRC. A study by Chen and colleagues indicates the hypothesis that MSCs improve tumorigenesis in IBD by inhibiting the expression of proinflammatory cytokines and activation of STAT3 [133]. In a study of azo-
of MSCs could lead to the dysregulation of the Wnt and TGF-β-Smad signaling pathways in the body, thus interfering with tumor initiation [134]. In the study of Feng and colleagues, low doses of ultraviolet radiation and X-ray irradiation caused BM-MSCs to secrete specific cytokines (TNF-α, IFN-γ) to inhibit CRC cell proliferation and induce apoptosis, showing antitumor effects [26].

Moreover, MSCs can play a tumor-suppressive role through microRNAs contained in exosomes, a paracrine mode. Yan et al. presented that miR-16-5p overexpression in BM-MSC-derived exosomes inhibits the proliferation, migration, and invasion of CRC cells and promotes the apoptosis of CRC cells by downregulating ITGA2 expression [135]. Chen and colleagues also demonstrated in in vitro cell experiments that BMSC-derived exosomal miR-4461 inhibits CRC cell proliferation, migration, and invasion by reducing COPB2 expression, suggesting that miR-4461 may be a potential target for diagnosis and treatment of CRC [136]. In addition, MSC-exosome-derived miR-3940-5p inhibits CRC cell invasion, EMT, and tumor growth and metastasis by targeting ITGA6 and subsequent TGF-β1 inactivation [137]. ADMSC-derived EVs carrying miR-15a inhibit the immune escape of CRC cells by the downregulation of the KDM4B/HOXC4/PD-L1 axis [138].

In addition to the anticancer effect of MSC exosomal miRNAs, Luetzkendorf and colleagues showed that human MSCs could be induced by the third-generation lentiviral vector system to produce TRAIL- (tumor necrosis factor-related apoptosis-inducing ligand-) MSCs. It has been demonstrated that TRAIL-MSCs can reduce tumor growth of

### Table 3: The different treatment options in CRC.

| Therapeutic method                  | Effects                                                                 | Reference |
|------------------------------------|-------------------------------------------------------------------------|-----------|
| Surgery                            | The cornerstone of CRC treatment                                         | [120]     |
| Chemotherapy                       | Prolongs survival and improves symptoms and quality of life             | [121]     |
| Radiotherapy                       | Achieves local control and improves long-term prognosis                | [122]     |
| Targeted therapy                   | Reduces potential liver metastasis associated with CRC (antiviral therapy) | [123]     |
| Immunotherapy                      | Achieves long-term durable remission in patients                        | [124, 125]|
| Probiotics                         | Enhance the immune barrier, regulate the intestinal immune state, inhibit pathogenic enzyme activity, regulate CRC cell proliferation and apoptosis, regulate redox homeostasis, and reprogram intestinal microbial composition | [126]     |
| Prebiotics                         | Stimulate the growth and/or activity of specific bacteria in the gut, improve host health, possess prebiotic potential, modulate gut microbiota composition, a product of fermentation metabolites, antiadhesive properties against pathogens, and alter the gene expression profile | [127]     |
| Postbiotics                        | Modulate the composition of the gut microbiota and the functionality of the immune system, promote the CRC treatment effectiveness, and reduces its side effects in CRC patients | [128]     |
| Antibiotics                        | Improve the treatment efficacy of oxaliplatin-based therapy and reduce cancer severity through controlling F. nucleatum | [129, 130]|
| Nonsteroidal anti-inflammatory drugs (NSAIDs) | Prolong survival time | [131]     |
| Fecal microbiota transplantation (FMT) | Restores the sensitivity of patients to anticancer drugs and enhances the immune response | [132]     |
CRC cells in vivo by inducing apoptosis [139]. Another study that supported the hypothesis showed that TRAIL-MSCs can induce the apoptosis of TRAIL-CRC-resistant cells and overcome the tumor resistance to TRAIL in clinical treatment, suggesting that MSCs can be used as a carrier for clinical cancer treatment [140]. Zheng et al. revealed that CXCR4 overexpression by BM-MSCs increases the ability of stem cells to nest in the intestinal tract and improves colitis-related tumorigenesis in mice [141]. Due to the limited data available, the clinical application of MSCs in the treatment of CRC remains controversial. The issue of the clinical therapeutic value of MSCs is an intriguing one that could be usefully explored in further research to promote the development of stem cell therapies.

5.2. Promoting Effects on CRC. Tumor-stromal interaction plays a key role in the biology of CRC. With the deepening of research on MSCs, recent studies show that MSCs are recruited from the bone marrow into tumor stroma and form an important component of the tumor microenvironment, being the main source of CAFs. It is involved in the regulation of intestinal inflammation, epithelial proliferation, stem cell maintenance, angiogenesis, and extracellular matrix remodeling and metastasis [142]. Wu et al. illustrated that the protumor effect of MSCs is attributable to the altered expression of cyclin and the inhibition of apoptosis, possibly through the AMPK/mTOR-mediated activation of NF-κB to promote the progression of CRC [143]. Similarly, Zhang and colleagues found that human CRC-derived MSCs promote the progression of CRC through IL-6/JAK2/STAT3 signaling and activate PI3K/AKT signaling [144]. A recent study showed that TGF-β1 can induce the differentiation of MSCs to CAFs through the activation of the JAK/STAT3 signaling pathway and promote migration and invasion of CRC cell lines HCT116 and HT29 cells [145]. Tan et al. revealed that the CXCR4/TGF-β1 axis plays an important role in the

| MSC-CRC interaction | Mode of function | Mechanisms | References |
|---------------------|-----------------|------------|------------|
| **Inhibition**       |                 |            |            |
| Cell-to-cell contact |                 | Inhibiting the expression of proinflammatory cytokines and STAT3 activation | [133] |
| Cell-to-cell contact |                 | Induces apoptosis and interferes with tumor initiation through the dysregulation of Wnt and TGF-β-Smad signaling pathways | [134] |
| Paracrine            |                 | miR-165-p overexpression in BM-MSC-exosomes inhibited the proliferation, migration, and invasion and promoted apoptosis of CRC cells by downregulating ITGA2 expression. | [135] |
| Paracrine            |                 | miR-4461 in BM-MSC-exosomes inhibits the proliferation, migration, and invasion of CRC cells by reducing the expression of COPB2. | [136] |
| Paracrine            |                 | MSC-exosome-derived miR-3940-5p inhibited CRC cell invasion, EMT, and metastasis by targeting ITGA6 and subsequent TGF-β1 inactivation. | [137] |
| Paracrine            |                 | miR-15a carried by AD-MSC-EVs restricted CRC immune escape by downregulating the KDM4b/HOXC4/PD-L1 axis. | [138] |
| **Promotion**        |                 | Regulating cell cycle and inhibiting apoptosis through the activation of NF-κB mediated by AMPK/mTOR | [143] |
| Cell-to-cell contact |                 | Promoting the progression of CRC cells through IL-6/JAK2/STAT3 signal | [144] |
| Cell-to-cell contact |                 | The activation of JAK/STAT3 stimulated by the TGF-β1 or CXCR4/TGF-β1 axis can induce MSCs to differentiate into CAFs, which can promote the progression of CRC. | [66, 145, 152] |
| Cell-to-cell contact |                 | Interacting with CRC cells through CCL3/4/5 -CCR5 to promote the growth of CRC tumors in vivo | [148] |
| Cell-to-cell contact |                 | Promoting the EMT process of CRC through the CCL5/β-catenin/Slug pathway and SPARC | [147, 151] |
| Cell-to-cell contact |                 | Activating the HER2/HER3-dependent PI3K/Akt signaling cascade in CRC cells by releasing soluble NRG1. | [149] |
| Cell-to-cell contact |                 | Affecting the early xenograft growth of CRC cells with specific α-catenin deficiency by secreting extracellular matrix | [150] |
| Cell-to-cell contact |                 | Regulating the P53/P21 pathway through posttranscriptional regulation helps CRC resist senescence. | [153] |
| Cell-to-cell contact |                 | Promoting CRC angiogenesis through paracrine’s high levels of the proangiogenic factor IL-8 | [154] |
| Paracrine            |                 | miR-222 targets ATF3 and inhibits the transcriptional activity of AKT1, thereby promoting malignant invasion and immune escape of CRC cells. | [157] |

Table 4: The effects of MSCs within the CRC microenvironment.
transformation of the tumor microenvironment by mediating the differentiation of MSCs to CAFs, promoting the growth and metastasis of CRCs [66].

In addition, studies by Nishikawa and colleagues have shown that MSCs interact with CRC cells through CCL3/4/5-CCR5, thereby promoting the growth of CRC tumors in vivo [146]. Chen et al. found that inflammation-activated human MSCs promote the epithelial-mesenchymal transformation (EMT) process and progression of CRC through the CCL5/-catenin-Slug pathway [147]. Similarly, it is reported that BM-MSCs are implanted in nude mice after subcutaneous injection of HCT116-cancer stem cells (CSCs) to construct xenograft tumors. BM-MSCs can promote the migration and invasion of CSCs in CRC, suggesting that it can be a potential therapeutic target for CRC [148]. Further studies by De Boeck and colleagues found that BM-MSCs stimulate the invasion, survival, and tumorigenesis of CRC cells by releasing soluble NRG1 and activating HER2/HER3-dependent PI3K/Akt signaling cascade in CRC cells, and the high expression of NRG1 is associated with poor prognosis [149].

In a study by Widder and colleagues, MSC-CRC interaction promoted the formation of three-dimensional globules in CRC cells with a dysfunctional E-cadherin system. Further analysis showed that MSCs may affect the early xenotransplantation growth of specific -catenin-deficient CRC cells by secreting extracellular matrix and ultimately play a cancer-promoting role [150]. EMT is an important mechanism for the progression of CRC, and SPARC is an important EMT-related factor in CRC, which is involved in the interaction between tumor cells and stromal cells. Naito and colleagues confirmed that MSCs induce the tumor-stromal formation and EMT process by expressing secreted protein acidic and rich in cysteine (SPARC) [151] and demonstrating a stronger ability to attack peripheral tissues through the mediation of newly expressed surface TGF- on MSCs after coculture with tumor cells [152], thereby promoting the occurrence and development of CRC.

In addition to MSCs playing a role in the proliferation, invasion, and migration of CRC cells, Li and colleagues also found that MSCs can regulate the PI3/P21 pathway through posttranscriptional regulation to help CRC resist senescence [153]. MSCs promote CRC angiogenesis and tumor growth through high levels of paracrine proangiogenic factor IL-8 [154]. Interestingly, besides the regulatory effects of MSCs on CRC cells, CRC cells can also induce morphological and functional changes of colon MSCs through secretion of exosomes, which is conducive to the growth and malignant progression of tumors [155], confirming the mutual promotion between the two. In addition to MSCs promoting the EMT process of CRC through direct cell-to-cell contact [156], recent studies by Li and colleagues found that miR-222 carried by extracellular vesicles derived from MSCs targets ATF3 binding and suppresses the transcriptional activity of AKT1, thereby promoting malignant invasion and immune escape of CRC cells [157].

6. Conclusion

Concerning CRC, various factors such as diet, environment, and genetic susceptibility greatly influence the constantly increasing incidence of CRC. The current cure rate of CRC is low, and the available treatment interventions are associated with a lot of side effects. MSC therapy has been highly regarded as a promising method for the treatment of clinical diseases including tumors. They have excellent conditions for the treatment of CRC due to their low immunogenicity, strong immune regulatory function, self-renewal ability, and easy accessibility. MSC-derived exosomes also express certain RNAs that participate in the inhibition of CRC growth and progression. These vesicles could also be engineered to serve as effective carriers of drugs and other therapeutic molecules to the CRC cells. However, like other malignancy studies, research on the application of MSCs in CRC is confronted with many challenges including the complex pathogenesis of CRC, the dual regulatory effects of MSCs on CRC, and the uncertainties of therapeutic dosage, administration mode, and adverse reactions shown in certain studies. Therefore, it is imperative to explore solutions to these hindrances, in addition to further investigating the regulatory mechanism and cargo sorting, functional modification, and carrier potentials of MSCs in CRC therapy for novel treatment interventions.

Conflicts of Interest

The authors declare that they have no competing interests

Authors’ Contributions

Jintao Yuan, Zhiping Wei, and Xinwei Xu contributed equally to this work.

Acknowledgments

The project of Zhenjiang Key Research and Development Plan (Social Development) (grant no. SH2019025) and Scientific Research Project of Health Commission of Jiangsu Province (grant no. ZZ2019036) are acknowledged. All authors approved the final version of the article.

References

[1] S. Viswanathan, Y. Shi, J. Galipeau et al., “Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature,” Cytotherapy, vol. 21, no. 10, pp. 1019–1024, 2019.
[2] S. Kern, H. Eicher, J. Stoever, H. Klüter, and K. Bieback, “Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue,” Stem Cells, vol. 24, no. 5, pp. 1294–1301, 2006.
[3] J. S. Heo, Y. Choi, H. S. Kim, and H. O. Kim, “Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue,” International journal of molecular medicine, vol. 37, no. 1, pp. 115–125, 2016.
[4] W. L. Fu, C. Y. Zhou, and J. K. Yu, "A new source of mesenchymal stem cells for articular cartilage repair: MSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs"
from bone marrow in a rabbit model,” The American journal of sports medicine, vol. 42, no. 3, pp. 592–601, 2014.

[5] M. Arévalo-Turrubiarte, C. Olmeo, P. Accornero, M. Baratta, and E. Martignani, “Analysis of mesenchymal cells (MSCs) from bone marrow, synovial fluid and mesenteric, neck and tail adipose tissue sources from equines,” Stem cell research, vol. 37, article 101442, 2019.

[6] M. Dominici, K. le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[7] T. Xu, Y. Zhang, P. Chang, S. Gong, L. Shao, and L. Dong, “Mesenchymal stem cell-based therapy for radiation-induced lung injury,” Stem cell research & therapy, vol. 9, no. 1, p. 18, 2018.

[8] S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005.

[9] C. Spano, G. Grisendi, G. Golinelli et al., “Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer,” Scientific reports, vol. 9, no. 1, article 37433, p. 1788, 2019.

[10] X. Chen, B. Yang, J. Tian et al., “Dental follicle stem cells ameliorate lipopolysaccharide-induced inflammation by secreting TGF-β3 and TSP-1 to elicit macrophage M2 polarization,” Cellular Physiology and Biochemistry, vol. 51, no. 5, pp. 2290–2308, 2018.

[11] M. Yañez-Mó, P. R. M. Siljander, Z. Andreu et al., “Biological properties of extracellular vesicles and their physiological functions,” Journal of extracellular vesicles, vol. 4, no. 1, article 27066, 2015.

[12] L. M. Doyle and M. Z. Wang, “Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis,” Cells, vol. 8, no. 7, p. 727, 2019.

[13] T. S. Chen, R. C. Lai, M. M. Lee, A. B. H. Choo, C. N. Lee, and S. K. Lim, “Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs,” Nucleic acids research, vol. 38, no. 1, pp. 215–224, 2010.

[14] Q. Qiu, G. Zheng, M. Ge et al., “Functional proteins of mesenchymal stem cell-derived extracellular vesicles,” Stem cell research & therapy, vol. 10, no. 1, article 1484, p. 359, 2019.

[15] J. Meldolesi, “Exosomes and ectosomes in intercellular communication,” Current Biology, vol. 28, no. 8, pp. R435–R444, 2018.

[16] S. Zhang, S. J. Chuah, R. C. Lai, J. H. P. Hui, S. K. Lim, and W. S. Toh, “MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity,” Biomaterials, vol. 156, pp. 16–27, 2018.

[17] P. Wu, B. Zhang, H. Shi, H. Qian, and W. Xu, “MSC-exosome: a novel cell-free therapy for cutaneous regeneration,” Cytotherapy, vol. 20, no. 3, pp. 291–301, 2018.

[18] R. C. Lai, F. Arslan, M. M. Lee et al., “Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury,” Stem cell research, vol. 4, no. 3, pp. 214–222, 2010.

[19] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a cancer journal for clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[20] J. Weitz, M. Koch, J. Debus, T. Höhler, P. R. Galle, and M. W. Büchler, “Colorectal cancer,” The Lancet, vol. 365, no. 9454, pp. 153–165, 2005.

[21] M. Navarro, A. Nicolas, A. Ferrandez, and A. Lanas, “Colorectal cancer population screening programs worldwide in 2016: an update,” World journal of gastroenterology, vol. 23, no. 20, pp. 3632–3642, 2017.

[22] A. Gini, E. E. L. Jansen, N. Zielonke et al., “Impact of colorectal cancer screening on cancer-specific mortality in Europe: a systematic review,” European journal of Cancer, vol. 127, pp. 224–235, 2020.

[23] D. E. Gerber, “Targeted therapies: a new generation of cancer treatments,” American family physician, vol. 77, no. 3, pp. 311–319, 2008.

[24] A. Rejhořová, A. Opattová, A. Čumová, D. Sliva, and P. Vodička, “Natural compounds and combination therapy in colorectal cancer treatment,” European journal of Medicine, vol. 144, pp. 582–594, 2018.

[25] S. François, B. Usunier, M. E. Forgue-Lafitte et al., “Mesenchymal stem cell administration attenuates colon cancer progression by modulating the immune component within the colorectal tumor microenvironment,” Stem cells translational medicine, vol. 8, no. 3, pp. 285–300, 2019.

[26] H. Feng, J. K. Zhao, T. S. Schiergens et al., “Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation,” British journal of cancer, vol. 118, no. 3, pp. 353–365, 2018.

[27] A. A. Hombach, U. Geumann, C. Günther, F. G. Hermann, and H. Abken, “IL7-IL12 engineered mesenchymal stem cells (MSCs) improve a CAR T cell attack against colorectal cancer,” Cells, vol. 9, no. 4, p. 873, 2020.

[28] K. Drela, L. Stanaszek, K. Sniøch et al., “Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death from the human femoral shaft as a new source of mesenchymal stem/stromal cells: an alternative cell material for banking and clinical transplantation,” Stem Cell Research & Therapy, vol. 11, no. 1, article 1697, p. 262, 2020.

[29] R. Hass, C. Kasper, S. Böhm, and R. Jacobs, “Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC,” Cell Communication and Signaling, vol. 9, no. 1, p. 12, 2011.

[30] K. E. Hawkins, M. Corellii, K. Dowding et al., “Embryonic stem cell-derived mesenchymal stem cells (MSCs) have a superior neuroprotective capacity over fetal MSCs in the hypoxic-ischemic mouse brain,” Stem cells translational medicine, vol. 7, no. 5, pp. 439–449, 2018.

[31] M. Bozorgmehr, S. Gurung, S. Darzi et al., “Endometrial and menstrual blood mesenchymal stem/stromal cells: biological properties and clinical application,” Frontiers in cell and developmental biology, vol. 8, pp. 497–497, 2020.

[32] M. M. Kamal and D. H. Kassem, “Pluripotent stem cells as a robust source of mesenchymal stem cells,” Stem Cell Reviews and Reports, vol. 13, no. 1, article 9695, pp. 68–78, 2017.

[33] Y. C. Lee, Y. H. Chan, S. C. Hsieh, W. Z. Lew, and S. W. Feng, “Comparing the osteogenic potentials and bone regeneration capacities of bone marrow and dental pulp mesenchymal stem cells in a rabbit calvarial bone defect model,” International journal of molecular sciences, vol. 20, no. 20, p. 5015, 2019.
[35] V. Chrep, B. Pitcher, M. A. Henry, and A. Diogenes, "Survival of the apical papilla and its resident stem cells in a case of advanced pulpal necrosis and apical periodontitis," Journal of endodontics, vol. 43, no. 4, pp. 561–567, 2017.

[36] H. Li, R. Ghazanfari, D. Zacharaki, H. C. Lim, and S. Scheding, "Isolation and characterization of primary bone marrow mesenchymal stromal cells," Annals of the New York Academy of Sciences, vol. 1370, no. 1, pp. 109–118, 2016.

[37] H. J. Buhring, V. L. Battula, S. Treml, B. Schewe, L. Kanz, and W. Vogel, "Novel markers for the prospective isolation of human MSC," Annals of the New York Academy of Sciences, vol. 1106, no. 1, pp. 262–271, 2007.

[38] M. Pierini, B. Dozza, E. Lucarelli et al., "Efficient isolation and enrichment of mesenchymal stem cells from bone marrow," Cytotherapy, vol. 14, no. 6, pp. 686–693, 2012.

[39] F. J. Lv, R. S. Tuan, K. M. C. Cheung, and V. Y. L. Leung, "Concise review: the surface markers and identity of human mesenchymal stem cells," Stem Cells, vol. 32, no. 6, pp. 1408–1419, 2014.

[40] H. J. Jin, Y. Bae, M. Kim et al., "Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy," International journal of molecular sciences, vol. 14, no. 9, pp. 17986–18001, 2013.

[41] P. Gentile, C. Calabrese, B. de Angelis, I. Pizzicannella, A. Kothari, and S. Garchovitch, "Impact of the different preparation methods to obtain human adipose-derived stromal vascular fraction cells (AD-SVFs) and human adipose-derived mesenchymal stem cells (AD-MSCs): enzymatic digestion versus mechanical centrifugation," International journal of molecular sciences, vol. 20, no. 21, p. 5471, 2019.

[42] S. L. Francis, S. Duchi, C. Onofrillo, C. di Bella, and P. F. M. Choong, "Adipose-derived mesenchymal stem cells in the use of cartilage tissue engineering: the need for a rapid isolation procedure," Stem cells international, vol. 2018, Article ID 8947548, 9 pages, 2018.

[43] E. T. Camilleri, M. P. Gustafson, A. Dudakovic et al., "Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production," Stem cell research & therapy, vol. 7, no. 1, p. 107, 2016.

[44] X. Zhang, M. Hirai, S. Cantero et al., "Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue," Journal of cellular biochemistry, vol. 112, no. 4, pp. 1206–1218, 2011.

[45] L. L. Lu, Y. J. Liu, S. G. Yang et al., "Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials," Haematologica, vol. 91, no. 8, pp. 1017–1026, 2006.

[46] N. Bezarovu, C. McKe, A. Alamri et al., "Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta," Journal of visualized experiments: JoVE, vol. 122, no. 122, 2017.

[47] K. E. Schwab and C. E. Gargett, "Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium," Human reproduction, vol. 22, no. 11, pp. 2903–2911, 2007.

[48] C. Trapero, A. Vidal, A. Rodriguez-Martinez et al., "The ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in human endometrium: a novel marker of basal stroma and mesenchymal stem cells," Purinergic Signal, vol. 15, no. 2, article 9656, pp. 225–236, 2019.

[49] H. Masuda, S. S. Anwar, H. J. Bühring, J. R. Rao, and C. E. Gargett, "A novel marker of human endometrial mesenchymal stem-like cells," Cell Transplant, vol. 21, no. 10, pp. 2201–2214, 2012.

[50] C. E. Gargett, K. E. Schwab, R. M. Zillwood, H. P. T. Nguyen, and D. Wu, "Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium," Biology of reproduction, vol. 80, no. 6, pp. 1136–1145, 2009.

[51] F. Rossignoli, A. Caselli, G. Grisendi et al., "Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood," BioMed research international, vol. 2013, Article ID 901821, 14 pages, 2013.

[52] J. Liu, F. Yu, Y. Sun et al., "Concise reviews: characteristics and potential applications of human dental tissue-derived mesenchymal stem cells," Stem Cells, vol. 33, no. 3, pp. 627–638, 2015.

[53] P. Hilkens, P. Gervoys, V. Fanton et al., "Effect of isolation methodology on stem cell properties and multilineage differentiation potential of human dental pulp stem cells," Cell and tissue research, vol. 353, no. 1, pp. 65–78, 2013.

[54] M. C. Ciuffreda, G. Malpasso, P. Musarò, V. Turco, and M. Gneccchi, "Protocols for in vitro differentiation of human mesenchymal stem cells into osteogenic, chondrogenic and adipogenic lineages," Methods in Molecular Biology, vol. 1416, pp. 149–158, 2016.

[55] N. S. Hwang, C. Zhang, Y. S. Hwang, and S. Varghese, "Mesenchymal stem cell differentiation and roles in regenerative medicine," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 1, no. 1, pp. 97–106, 2009.

[56] F. Ng, S. Boucher, S. Koh et al., "PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages," Blood, vol. 112, no. 2, pp. 295–307, 2008.

[57] F. Viti, M. Landini, A. Mezzelani, L. Petecchia, L. Milanesi, and S. Scaglione, "Osteogenic differentiation of MSC through calcium signaling activation: transcriptomics and functional analysis," PLoS One, vol. 11, no. 2, article e0148173, 2016.

[58] L. You, L. Pan, L. Chen, W. Gu, and J. Chen, "miR-27a is essential for the shift from osteogenic differentiation to adipogenic differentiation of mesenchymal stem cells in post-menopausal osteoporosis," Cellular Physiology and Biochemistry, vol. 39, no. 1, pp. 253–265, 2016.

[59] S. G. Almalki and D. K. Agrawal, "Key transcription factors in the differentiation of mesenchymal stem cells," Differentiation, vol. 92, no. 1–2, pp. 41–51, 2016.

[60] J. D. Chen, F. F. Xu, H. Zhu et al., "ICAM-1 regulates differentiation of MSC to adipocytes via activating MAPK pathway," Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 22, no. 1, pp. 160–165, 2014.

[61] J. L. Crane and X. Cao, "Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling," The Journal of clinical investigation, vol. 124, no. 2, pp. 466–472, 2014.
F. Liu, H. Qiu, M. Xue et al., “MSC encapsulation in alginate microcapsules prolongs survival after intrarticular injection, a longitudinal in vivo cell and bead integrity tracking study,” Cell Biology and Toxicology, vol. 36, no. 6, article 9532, pp. 553–570, 2020.

T. L. Whiteside, “Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment,” Seminars in immunology, vol. 35, pp. 69–79, 2018.

W. N. Brennen, B. Zhang, I. Kulac et al., “Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate,” Oncotarget, vol. 8, no. 29, article 17362, pp. 46710–46727, 2017.

R. M. Hughes, B. W. Simons, H. Khan et al., “Asporin restricts mesenchymal stromal cell differentiation, alters the tumor microenvironment, and drives metastatic progression,” Cancer research, vol. 79, no. 14, pp. 3636–3650, 2019.

H. X. Tan, Z. G. Xiao, T. Huang, Z. X. Fang, Y. Liu, and Z. C. Huang. “CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development,” Cancer biology & therapy, vol. 21, no. 3, pp. 248–257, 2020.

G. Zheng, R. Huang, G. Qiu et al., “Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis,” Cell and tissue research, vol. 374, no. 1, article 2871, pp. 1–15, 2018.

M. François, R. Romieu-Mouriez, M. Li, and J. Galipeau, “Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation,” Molecular Therapy, vol. 20, no. 1, pp. 187–195, 2012.

S. F. H. de Witte, F. Luk, J. M. Sierra Parraga et al., “Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by mononuclear cells,” Stem Cells, vol. 36, no. 4, pp. 602–615, 2018.

G. R. Willis, A. Fernandez-Gonzalez, J. Anastas et al., “Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation,” American journal of respiratory and critical care medicine, vol. 197, no. 1, pp. 104–116, 2018.

F. Liu, H. Qiu, M. Xue et al., “MSC-secreted TGF-β regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway,” Stem cell research & therapy, vol. 10, no. 1, article 1447, p. 345, 2019.

A. B. Vasandan, S. Jahnavi, C. Shashank, P. Prasad, A. Kumar, and S. J. Prasanna, “Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism,” Scientific Reports, vol. 6, no. 1, article 38308, 2016.

Y. Li, D. Zhang, L. Xu et al., “Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models,” Cellular & molecular immunology, vol. 16, no. 12, pp. 908–920, 2019.

S. Zhang, K. Y. W. Teo, S. J. Chua, R. C. Lai, S. K. Lim, and W. S. Toh, “MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis,” Biomaterials, vol. 200, pp. 35–47, 2019.

K. Pakravan, S. Babashah, M. Sadeghizadeh et al., “MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells,” Cellular oncolgy, vol. 40, no. 5, pp. 457–470, 2017.

M. Ono, N. Kosaka, N. Tominaga et al., “Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells,” Science signaling, vol. 7, no. 332, p. ra63, 2014.

L. J. Wei, D. M. Bai, Z. Y. Wang, and B. C. Liu, “MicroRNA-375 accelerates the invasion and migration of colorectal cancer through targeting RECK,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 11, pp. 4738–4745, 2019.

C. Melzer, J. von der Ohe, and R. Hass, “Enhanced metastatic capacity of breast cancer cells after interaction and hybrid formation with mesenchymal stroma/stem cells (MSC),” Cell Communication and Signaling, vol. 16, no. 1, p. 2, 2018.

L. Wang, S. Huang, S. Li et al., “Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study,” Drug design, development and therapy, vol. 13, pp. 4331–4340, 2019.

N. H. Riordan, I. Morales, G. Fernández et al., “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis,” Journal of translational medicine, vol. 16, no. 1, p. 57, 2018.

P. Petrou, I. Kassis, N. Levin et al., “Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis,” Brain, vol. 143, no. 12, pp. 3574–3588, 2020.

M. A. Matthay, C. S. Calfee, H. Zhuo et al., “Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomized phase 2a safety trial,” The Lancet Respiratory Medicine, vol. 7, no. 2, pp. 154–162, 2019.

J. Bartolucci, F. J. Verdugo, P. L. González et al., “Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]),” Circulation research, vol. 121, no. 10, pp. 1192–1204, 2017.

J. C. von Einem, C. Guenther, H. D. Volk et al., “Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the phase 1/2 TREAT-ME-1 trial,” International journal of cancer, vol. 145, no. 6, pp. 1538–1546, 2019.

M. T. Schweizer, H. Wang, T. J. Bivalacqua et al., “A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer,” Stem Cells Translational Medicine, vol. 8, no. 5, pp. 441–449, 2019.

T. J. Morrison, M. V. Jackson, E. K. Cunningham et al., “Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer,” American journal of respiratory and critical care medicine, vol. 196, no. 10, pp. 1275–1286, 2017.

Y. Yao, X. L. Fan, D. Jiang et al., “Connexin 43-mediated mitochondrial transfer of iPSC-MSCs alleviates asthma inflammation,” Stem Cell Reports, vol. 11, no. 5, pp. 1120–1135, 2018.

Y. Chen, F. Zhang, D. Wang et al., “Mesenchymal stem cells attenuate diabetic lung fibrosis via adjusting Sirt3-mediated
stress responses in rats,” *Oxidative medicine and cellular longevity*, vol. 2020, Article ID 8076105, 15 pages, 2020.

[89] Y. Liang, D. Zhang, L. Li et al., “Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2,” *Stem cell research & therapy*, vol. 11, no. 1, article 1580, p. 87, 2020.

[90] S. Soontararak, L. Chow, V. Johnson et al., “Extracellular vesicles improve post-stroke neuroregeneration and prevent posts ischemic immunosuppression,” *Stem cells translational medicine*, vol. 4, no. 10, pp. 1131–1143, 2015.

[91] T. R. Doeppper, J. Herz, A. Gorgens et al., “Mesenchymal stem cells promote healing in intestinal healing and microbiome normalization in mouse inflammatory bowel disease model,” *Stem Cells Translational Medicine*, vol. 7, no. 6, pp. 456–467, 2018.

[92] X. Cao, L. Duan, H. Hou et al., “Mesenchymal stem cells reduce murine colonic inflammation via a macrophage-dependent mechanism,” *JCI Insight*, vol. 4, no. 24, 2019.

[93] Y. Li, Q. He, L. Wang, R. Zhao et al., “Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell responses,” *Journal of the Formosan Medical Association*, vol. 120, no. 1, pp. 602–608, 2021.

[94] F. Radmanesh, M. Mahmoudi, E. Yazdianpanah et al., “The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus,” *IUBMB Life*, vol. 72, no. 11, pp. 2366–2381, 2020.
Stem Cells International

[118] E. Saus, S. Iraola-Guzmán, J. R. Willis, A. Brunet-Vega, and T. Gabaldón, "Microbiome and colorectal cancer: roles in carcinogenesis and clinical potential," Molecular aspects of medicine, vol. 69, pp. 93–106, 2019.

[119] M. F. Tolba, "Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors," International journal of cancer, vol. 147, no. 11, pp. 2996–3006, 2020.

[120] I. Koliarakis, E. Athanasakis, M. Sgantzos et al., "Intestinal microbiota in colorectal cancer surgery," Cancers (Basel), vol. 12, no. 10, p. 3011, 2020.

[121] G. Pupwe, O. Ngalamika, and J. Akudugu, "Chemotherapy for elderly colorectal cancer patients at a tertiary hospital in South Africa," The Pan African Medical Journal, vol. 37, p. 100, 2020.

[122] M. Park, J. Kwon, H.-J. Shin et al., "Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids," International journal of oncology, vol. 57, no. 6, pp. 1307–1318, 2020.

[123] Q. Wang and C. R. Yu, "Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: an appraisal," World journal of clinical cases, vol. 8, no. 11, pp. 2111–2115, 2020.

[124] D. Y. Lizardo, C. Kuang, S. Hao, J. Yu, Y. Huang, and L. Zhang, "Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside," Biotechmica et Biophysiaca Acta (BBA)-Reviews on Cancer, vol. 1874, no. 2, article 188447, 2020.

[125] K. Ganesh, Z. K. Stadler, A. Cercek et al., "Immunotherapy in colorectal cancer: rationale, challenges and potential," Nature reviews Gastroenterology & hepatology, vol. 16, no. 6, pp. 361–375, 2019.

[126] S. Ding, C. Hu, J. Fang, and G. Liu, "The protective role of probiotics against colorectal cancer," Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 8884583, 10 pages, 2020.

[127] W. Fong, Q. Li, and J. Yu, "Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer," Oncogene, vol. 39, no. 26, article 1341, pp. 4925–4943, 2020.

[128] A. H. Rad, L. Aghebati-Maleki, H. S. Kafil, and A. Abbasi, "Molecular mechanisms of postbiotics against colorectal cancer prevention and treatment," Critical reviews in food science and nutrition, vol. 61, no. 11, pp. 1787–1803, 2021.

[129] H. Imai, K. Saijo, K. Komine et al., "Antibiotics improve the treatment efficacy of oxaliplatin-based but not irinotecan-based therapy in advanced colorectal cancer patients," Journal of oncology, vol. 2020, Article ID 1701326, 8 pages, 2020.

[130] D. J. Slade, "New Roles for Fuso bacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?", Trends Cancer, vol. 7, no. 3, pp. 185–187, 2021.

[131] S. K. H. Li and A. Martin, "Mismatch repair and colon cancer: mechanisms and therapies explored," Trends in molecular medicine, vol. 22, no. 4, pp. 274–289, 2016.

[132] A. Parisi, G. Porzio, F. Pulcini et al., "What is known about theragnostic strategies in colorectal cancer," Biomedicines, vol. 9, no. 2, p. 140, 2021.

[133] Z. Chen, X. He, X. He et al., "Bone marrow mesenchymal stem cells ameliorate colitis-associated tumorigenesis in mice," Biochemical and Biophysical Research Communications, vol. 450, no. 4, pp. 1402–1408, 2014.

[134] M. Nasuno, Y. Arimura, K. Nagaishi et al., "Mesenchymal stem cells cancel azoxymethane-induced tumor initiation," Stem Cells, vol. 32, no. 4, pp. 913–925, 2014.

[135] Y. Xu, L. Shen, F. Li, J. Yang, X. Wan, and M. Ouyang, "microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGAV2," Journal of cellular physiology, vol. 234, no. 11, pp. 21380–21394, 2019.

[136] H. L. Chen, J. J. Li, F. Jiang, W. J. Shi, and G. Y. Chang, "MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer," Bioscience, biotechnology, and biochemistry, vol. 84, no. 2, pp. 338–346, 2020.

[137] T. Li, Y. Wan, Z. Su, J. Li, M. Han, and C. Zhou, "Mesenchymal stem cell-derived exosomal microRNA-3940-5p inhibits colorectal cancer metastasis by targeting integrin α6," Digestive Diseases and Sciences, vol. 66, no. 6, article 6458, pp. 1916–1927, 2021.

[138] L. Liu, T. Yu, Y. Jin, W. Mai, J. Zhou, and C. Zhao, "MicroRNA-15a carried by mesenchymal stem cell-derived extracellular vesicles inhibits the immune evasion of colorectal cancer cells by regulating the KDM4B/FOXO4/PTEN axis," Frontiers in cell and developmental biology, vol. 9, article 629893, 2021.

[139] J. Luetzkendorf, L. P. Mueller, T. Mueller, H. Caya, K. Nerger, and H. J. Schmoll, "Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence," Journal of cellular and molecular medicine, vol. 14, no. 9, pp. 2292–2304, 2010.

[140] L. P. Mueller, J. Luetzkendorf, M. Widder, K. Nerger, H. Caya, and T. Mueller, "TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo," Cancer gene therapy, vol. 18, no. 4, pp. 229–239, 2011.

[141] X. B. Zheng, X. W. He, L. J. Zhang et al., "Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice," Gastroenterology report, vol. 7, no. 2, pp. 127–138, 2019.

[142] V. Koliaraki, C. K. Pallangyo, F. R. Greten, and G. Kollias, "Mesenchymal cells in colon cancer," Gastroenterology, vol. 152, no. 5, pp. 964–979, 2017.

[143] X. B. Wu, Y. Liu, G. H. Wang et al., "Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-kB activation," Scientific reports, vol. 6, no. 1, article 21420, 2016.

[144] X. Zhang, F. Hu, G. Li et al., "Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling," Cell death & disease, vol. 9, no. 2, p. 25, 2018.

[145] H. X. Tan, Z. B. Cao, T. T. He, T. Huang, C. L. Xiang, and Y. Liu, "TGFβ1 is essential for MSCs-CAFs differentiation and promotes HCT116 cells migration and invasion via JAK/STAT3 signaling," Oncotargets and therapy, vol. 12, pp. 5323–5334, 2019.

[146] G. Nishikawa, K. Kawada, J. Nakagawa et al., "Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5," Cell death & disease, vol. 10, no. 4, p. 264, 2019.
[147] K. Chen, Q. Liu, L. L. Tsang et al., “Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5/β-catenin/Slug pathway,” *Cell death & disease*, vol. 8, no. 5, article e2819, 2017.

[148] W. Zou, J. Zhao, Y. Li et al., “Rat bone marrow-derived mesenchymal stem cells promote the migration and invasion of colorectal cancer stem cells,” *OncoTargets and therapy*, vol. 13, pp. 6617–6628, 2020.

[149] A. de Boeck, P. Pauwels, K. Hensen et al., “Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling,” *Gut*, vol. 62, no. 4, pp. 550–560, 2013.

[150] M. Widder, J. Lützkendorf, H. Caysa et al., “Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-integrin-dependent mechanism,” *International journal of cancer*, vol. 138, no. 4, pp. 964–975, 2016.

[151] T. Naito, R. Yuge, Y. Kitadai et al., “Mesenchymal stem cells induce tumor stroma formation and epithelial-mesenchymal transition through SPARC expression in colorectal cancer,” *Oncology reports*, vol. 45, no. 6, 2021.

[152] V. Mele, M. G. Muraro, D. Calabrese et al., “Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β,” *International journal of cancer*, vol. 134, no. 11, pp. 2583–2594, 2014.

[153] G. Li, R. Zhang, X. Zhang, S. Shao, F. Hu, and Y. Feng, “Human colorectal cancer derived-MSCs promote tumor cells escape from senescence via P53/P21 pathway,” *Clinical and Translational Oncology*, vol. 22, no. 4, pp. 503–511, 2020.

[154] J. Wang, Y. Wang, S. Wang et al., “Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer,” *Oncotarget*, vol. 6, no. 40, pp. 42825–42837, 2015.

[155] L. Lugini, M. Valtieri, C. Federici et al., “Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells,” *Oncotarget*, vol. 7, no. 31, article 10574, pp. 50086–50098, 2016.

[156] H. Takigawa, Y. Kitadai, K. Shinagawa et al., “Mesenchymal stem cells induce epithelial to mesenchymal transition in colon cancer cells through direct cell-to-cell contact,” *Neoplasia*, vol. 19, no. 5, pp. 429–438, 2017.

[157] S. Li, G. Yan, M. Yue, and L. Wang, “Extracellular vesicles-derived microRNA-222 promotes immune escape via interacting with ATF3 to regulate AKT1 transcription in colorectal cancer,” *BMC Cancer*, vol. 21, no. 1, article 8063, p. 349, 2021.